Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | CIO | May 10, 2018 | May 10, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date May 10, 2018 · Filed May 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,167 |
Reported balance
After 2018-05-10 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2018-05-10 · Exercise / conversion · Acquired 33,667 · Balance 38,167 |
| Common StockSEC Table I · non-derivative | Direct | 64,833 |
Reported balance
After 2018-05-10 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2018-05-10 · Exercise / conversion · Acquired 26,666 · Balance 64,833 |
| Common StockSEC Table I · non-derivative | Direct | 86,499 |
Reported balance
After 2018-05-10 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2018-05-10 · Exercise / conversion · Acquired 21,666 · Balance 86,499 |
| Common StockSEC Table I · non-derivative | Direct | 4,500 |
Reported balance
After 2018-05-10 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2018-05-10 · Sale · Disposed 81,999 · Balance 4,500 |
| Common StockSEC Table I · non-derivative | Direct | 4,500 |
Reported balance
Holding disclosure · report date 2018-05-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,500 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.78 · Expires 2020-05-06 | Direct | 0 |
Reported balance
After 2018-05-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-10 · Other · Disposed 33,667 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.15 · Expires 2021-04-20 | Direct | 13,334 |
Reported balance
After 2018-05-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-10 · Other · Disposed 26,666 · Balance 13,334 F1: On April 20, 2016, Mr. Ross was granted 40,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Mr. Ross exercised 26,666 of these options in May 2018, leaving a balance of 13,334 options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.52 · Expires 2022-04-28 | Direct | 43,334 |
Reported balance
After 2018-05-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-10 · Other · Disposed 21,666 · Balance 43,334 F2: On April 28, 2017, Mr. Ross was granted 65,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Mr. Ross exercised 21,666 of these options in May 2018, leaving a balance of 43,334 options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.03 · Expires 2023-02-26 | Direct | 72,500 |
Reported balance
Holding disclosure · report date 2018-05-10 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 72,500 F3: On February 26, 2018, Mr. Ross was granted 72,500 stock options. These options vest ratably over the first three anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 20, 2016, Mr. Ross was granted 40,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Mr. Ross exercised 26,666 of these options in May 2018, leaving a balance of 13,334 options.
F2: On April 28, 2017, Mr. Ross was granted 65,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Mr. Ross exercised 21,666 of these options in May 2018, leaving a balance of 43,334 options.
F3: On February 26, 2018, Mr. Ross was granted 72,500 stock options. These options vest ratably over the first three anniversary dates of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2018 Filed May 10, 2018 21:53 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to Buy) · Derivative | 21,666 | $7.52 Strike: $7.52 | $162,928.32 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · derivative · entry 8 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,334 Underlying: Common Stock · 21,666 shares Expires 2022-04-28 F2 · derivative.exercise_date: On April 28, 2017, Mr. Ross was granted 65,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Mr. Ross exercised 21,666 of these options in May 2018, leaving a balance of 43,334 options. Read SEC document |
| May 10, 2018 Filed May 10, 2018 21:53 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to Buy) · Derivative | 26,666 | $7.15 Strike: $7.15 | $190,661.90 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · derivative · entry 7 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,334 Underlying: Common Stock · 26,666 shares Expires 2021-04-20 F1 · derivative.exercise_date: On April 20, 2016, Mr. Ross was granted 40,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Mr. Ross exercised 26,666 of these options in May 2018, leaving a balance of 13,334 options. Read SEC document |
| May 10, 2018 Filed May 10, 2018 21:53 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to Buy) · Derivative | 33,667 | $4.78 Strike: $4.78 | $160,928.26 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · derivative · entry 6 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,667 shares Expires 2020-05-06 Read SEC document |
| May 10, 2018 Filed May 10, 2018 21:53 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 81,999 | $10.78 | $883,949.22 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · nonDerivative · entry 5 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Read SEC document |
| May 10, 2018 Filed May 10, 2018 21:53 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 21,666 | $7.52 | $162,928.32 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · nonDerivative · entry 4 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2018 Filed May 10, 2018 21:53 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 26,666 | $7.15 | $190,661.90 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · nonDerivative · entry 3 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2018 Filed May 10, 2018 21:53 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 33,667 | $4.78 | $160,928.26 |
DisclosureSEC source: 0001077183-18-000019 · wf-form4_152598912661973.xml · nonDerivative · entry 2 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:45 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option(Right to Buy) · Derivative | 72,500 | $8.03 Strike: $8.03 | $582,175.00 |
DisclosureSEC source: 0001209191-18-014676 · doc4.xml · derivative · entry 5 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2023-02-26 F4 · derivative.exercise_date: On February 26, 2018, Mr. Ross was granted 72,500 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 20:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon stock | 45,833 | $7.79 | $357,039.07 |
DisclosureSEC source: 0001209191-17-038136 · doc4.xml · nonDerivative · entry 6 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 20:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to Buy) · Derivative | 33,333 | $4.78 Strike: $4.78 | $159,331.74 |
DisclosureSEC source: 0001209191-17-038136 · doc4.xml · derivative · entry 9 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,667 Underlying: Common Stock · 67,000 shares Expires 2020-05-06 F3 · derivative.exercise_date: On May 6, 2015, Mr. Ross was granted 100,000 stock options to purchase common stock of the Company. These options vest ratably on each of the first three anniversary dates of the grant date. On May 9, 2016, Mr. Ross exercised 15,000 of these options leaving a balance of 85,000 options and on May 18, 2016, Mr. Ross exercised 18,000 of these options leaving a balance of 67,000 options. On June 2, 2017, Mr. Ross exercised 33,333 of these options leaving a balance of 33,667 options. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 20:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to buy) · Derivative | 37,500 | $3.93 Strike: $3.93 | $147,375.00 |
DisclosureSEC source: 0001209191-17-038136 · doc4.xml · derivative · entry 8 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2018-04-22 F2 · derivative.exercise_date: On April 22, 2013, Mr. Ross was granted 150,000 stock options to purchase common stock of the Company. These options vest ratably on each of the next 4 anniversary dates of the grant date. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 20:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 10,000 | $7.79 | $77,900.00 |
DisclosureSEC source: 0001209191-17-038136 · doc4.xml · nonDerivative · entry 5 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,333 Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 20:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 15,000 | $7.63 | $114,450.00 |
DisclosureSEC source: 0001209191-17-038136 · doc4.xml · nonDerivative · entry 4 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,333 Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 20:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 33,333 | $4.78 | $159,331.74 |
DisclosureSEC source: 0001209191-17-038136 · doc4.xml · nonDerivative · entry 3 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 20:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 37,500 | $3.93 | $147,375.00 |
DisclosureSEC source: 0001209191-17-038136 · doc4.xml · nonDerivative · entry 2 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2017 Filed May 2, 2017 20:33 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $7.52 Strike: $7.52 | $488,800.00 |
DisclosureSEC source: 0001209191-17-029207 · doc4.xml · derivative · entry 5 ROSS STEVEN A · CIK 0001591976 · CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2022-04-28 F4 · derivative.exercise_date: On April 28, 2017, Mr. Ross was granted 65,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.